Showing 1 - 10 of 743
EU countries closely regulate pharmaceutical prices whereas the U.S. does not. This paper shows how price constraints affect the profitability, stock returns, and R&D spending of EU and U.S. firms. Compared to EU firms, U.S. firms are more profitable, earn higher stock returns, and spend more on...
Persistent link: https://www.econbiz.de/10005248744
In 2005, as the result of a World Trade Organization mandate, India began to implement product patents for pharmaceuticals that were compliant with the 1995 Trade-Related Aspects of Intellectual Property Rights (TRIPS). We combine pharmaceutical product sales data for India with a newly gathered...
Persistent link: https://www.econbiz.de/10010950922
We examine the relationship between patent protection for pharmaceuticals and investment in development of new drugs. Patent protection has increased around the world as a consequence of the TRIPS Agreement, which specifies minimum levels of intellectual property protection for members of the...
Persistent link: https://www.econbiz.de/10008625935
Patent protection spurs innovation by raising the rewards for research, but it usually results in less desirable … allocations after the innovation has been discovered. In effect, patents reward inventors with inefficient monopoly power. However …
Persistent link: https://www.econbiz.de/10005774382
This paper studies how patent rights and price regulation affect how fast new drugs are launched in different countries, using newly constructed data on launches of 642 new drugs in 76 countries for the period 1983-2002, and information on the duration and content of patent and price control...
Persistent link: https://www.econbiz.de/10010950846
Do intellectual property (IP) rights on existing technologies hinder subsequent innovation? Using newly-collected data …'s short-term IP had persistent negative effects on subsequent innovation relative to a counterfactual of Celera genes having …
Persistent link: https://www.econbiz.de/10008540042
This paper exploits a sharp reduction in patient cost sharing at age 70 in Japan, using a regression discontinuity design to examine its effect on utilization, health, and financial risk arising from out-of-pocket expenditures. Due to the national policy, cost sharing is 60-80 percent lower at...
Persistent link: https://www.econbiz.de/10010969410
Background. In Spain's "MIR" system of allocating residency training positions, medical school graduates are ranked according to their performance on a national exam and then sequentially choose from the remaining available training slots. We studied how changes in the MIR system might address...
Persistent link: https://www.econbiz.de/10010969452
In a field experiment in Uganda, we find that demand after a free distribution of three health products is lower than after a sale distribution. This contrasts with work on insecticide-treated bed nets, highlighting the importance of product characteristics in determining pricing policy. We put...
Persistent link: https://www.econbiz.de/10010950656
This review discusses the role of consumer-directed and physician-directed promotion in the pharmaceutical market, based on the classic conceptual framework of whether such promotion is "persuasive" and/or "informative". Implications for public health and welfare partly depend on whether, and to...
Persistent link: https://www.econbiz.de/10010950788